CUMBERLAND PHARMACEUTICALS INC 8-K

What Happened
Cumberland Pharmaceuticals (CPIX) filed an 8-K reporting that on April 22, 2026 it signed an Asset Purchase Agreement to sell specified FDA-approved U.S. branded products to an affiliate of Apotex Inc. for $100,000,000 payable at closing. The Board unanimously approved the Transaction; shareholder approval is required. Cumberland will keep its Cumberland Emerging Technologies business and its ifetroban product candidates to continue development after closing.

Key Details

• Purchase price: $100,000,000 payable at closing.
• Assets being sold include Acetadote®, Caldolor®, Kristalose®, Sancuso®, Vaprisol®, Vibativ® and certain product-related equity interests.
• Retained programs: Cumberland Emerging Technologies, Inc. and the Company’s ifetroban candidates remain with Cumberland.
• Governance/approvals: Board recommends shareholder approval; certain directors and executives holding ~41% of shares signed Voting & Support Agreements to vote in favor and not transfer those shares.
• Timing and fees: Agreement can be terminated if not closed by August 20, 2026; Cumberland may owe a $4,000,000 termination fee in specified cases, and Apotex would owe a $4,000,000 reverse fee if it fails to close when able.
• Other terms: customary closing conditions, reps/warranties, indemnities, an 18‑month mutual non-solicit/non-hire, and a 4‑year non-compete/non-interference on Cumberland. VelocityHealth gave a fairness opinion (April 15, 2026) that the consideration is fair.

Why It Matters
The deal would provide Cumberland with immediate cash proceeds of $100M while allowing the company to focus on its retained development programs (including ifetroban). Shareholder approval and customary closing conditions are required, so timing and completion are not guaranteed. The Voting & Support Agreements (holders of ~41% of shares) increase the likelihood of approval, but investors should note the termination fees, non-compete restrictions, and customary deal risks disclosed in the filing. A proxy statement and more details will be filed ahead of the shareholder vote.